Objective To evaluate the combined application of BCL-2 and myc gene expression in the diagnosis of breast cancer. Methods The expression of BCL-2 and myc were detected by FQ-PCR 15 health women,30 patients with benign breast disease and 140 patients with breast cancer. Β2-microglobin was used as internal control. Results The ratio of BCL-2 and myc divided by β2-microglobin in health women , patients with benign breast disease and patients with breast cancer were (1. 32±0.12)×10-3, (1. 31 ± 0. H)×10-3,(6.36±1.02)×10-3,(1.14±0.07)×10-3,(1.15±0.06)×10-3,and (2.77±1.41)×10-30.There was no significant difference between normal controls and patients with benign breast disease (P > 0.05). The ratio of BCL-2 and myc divided by β2-microglo- bin in patients with breast cancer was higher than that in the other groups (P < 0. 05). There was no difference in β2 -microglobin a- mong three groups(P > 0.05). The sensitivity of BCL-2 and myc gene expression by the combined detection was higher than that by single gene detection. Conclusions FQ-PCR is a rapid method for quantitating BCL-2 and myc. The combined detection can improve the sensitivity of diagnosis in breast cancer.%目的 探讨联合检测 B 细胞淋巴瘤/白血病-2 基因(B cell lymphoma /leukemia 2 gene,BCL-2)与核内原癌基因 (Nuclear oncogene,myc)基因表达水平在乳腺癌诊断和治疗监测中的应用.方法 建立荧光定量聚合酶链反应(FQ-PCR)法,并以β2 -微球蛋白为内对照测定 15 名健康女性体检者(正常对照组)、30 例良性乳腺疾病患者(良性乳腺疾病组)和 140 例乳 腺癌患者(乳腺癌组)外周血中 BCL-2 和 myc 的表达量.结果 BCL-2 和 myc 表达水平与β2 -微球蛋白的比值在健康女性体 检者、良性乳腺疾病和乳腺癌患者分别为(1.32±0.12)×10-3,(1.31±0.11)×10-3,(6.36±1.02)×10-3,(1.14±0.07)×10-3,(1.15±0.06×)10-3,(2.77±1.41)×10-3,在正常对照组和良性乳腺疾病组间差异无统计学意义(P ＞0.05),乳腺癌组均高于前 两组(P ＜0.05),3 组β2 -微球蛋白差异无统计学意义(P ＞0.05);BCL-2 与 myc 联合检测的灵敏度高于单个基因的检测.结 论 FQ-PCR 技术可以快速定量检测 BCL-2 和 myc mRNA,两者联合检测可有效提高对乳腺癌诊断的灵敏度.
展开▼
